Moderna (MRNA) - Get Report and BioNTech (BNTX) - Get Report are expecting to receive emergency approval from the European Union to distribute their respective Covid-19 vaccines as early as next month.
The European Medicines Agency and the U.S. Food and Drug Administration are in daily contact with each other and with the front-runner vaccine makers in an effort to synchronize their efforts to begin distributing their respective vaccines in the second half of December.
The speedy regulatory assessment and focus on multi-regional efforts comes as the U.S. and many European countries face fierce new waves of the disease. More than 1 million new coronavirus cases have been reported in the U.S. over the past week, prompting the Centers for Disease Control and Prevention to urge Americans to avoid travel for Thanksgiving.
The EU has already secured up to 300 million doses of the Pfizer-BioNTech vaccine, and has also cut supply agreements with other frontrunner candidates from AstraZeneca (AZN) - Get Report, Sanofi (SNY) - Get Report, Johnson & Johnson (JNJ) - Get Report, and CureVac (CVAC) - Get CureVac N.V. Report, according to Bloomberg.
In the U.S., Pfizer and BioNTech on Friday filed for emergency use authorization with the FDA for their Covid-19 vaccine.